The state of Montana has sued Eli Lilly and Co. for marketing its Zyprexa antipsychotic drug for off-label uses—the seventh state to make such claims.

The lawsuit alleges the Indianapolis drugmaker owes the state for drug costs and harming patients after promoting the drug to sedate nursing home patients and giving kickbacks to doctors, according to Bloomberg. Zyprexa, which turned nearly $4.4 billion in sales last year, is only approved for treating schizophrenia and bipolar disorder.

Brought March 7, the Montana suit also claims Lilly launched a sales force with 280 people to market the drug for off-label uses.

Lilly has committed to as much as $1.2 billion to settle approximately 28,500 claims from Zyprexa users.

Bloomberg said Lilly didn't respond to requests for comment.